Opinion
Video
Factors Driving 3L Therapeutic Selection for mCRC
Author(s):
Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).
EP: 1.Overview of Molecular Testing and Barriers in mCRC
EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC
EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
EP: 4.Exploring Toxicities for Second Line Treatments in mCRC
EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
Now Viewing
EP: 6.Factors Driving 3L Therapeutic Selection for mCRC
EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial
EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC
EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR
EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer
- Dr Marshall to Panel:Please outline your approach to treatment selection for patients with mCRC in the 3L setting and discuss factors influencing your choice of therapy.
- Dr Cohen: In which patients would you consider fruquintinib versus TAS-102 ± bevacizumab?
- Dr Marshall: For which patients would you deviate from this approach and why you might make this decision?
- Dr Cohen: In which patients would you consider fruquintinib versus TAS-102 ± bevacizumab?
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
